Company news

Verastem, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

January 4, 2021

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

December 14, 2020

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

November 29, 2020

Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress

November 8, 2020

Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors

October 27, 2020

Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio

September 29, 2020

Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit

September 15, 2020

Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study

September 13, 2020

Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors

August 9, 2020

Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

August 9, 2020

Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma

June 21, 2020

Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference

May 27, 2020

Verastem Oncology Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

May 6, 2020

Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I

April 26, 2020

Verastem Oncology Appoints John H. Johnson to its Board of Directors

April 22, 2020

Verastem Oncology Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

April 20, 2020

Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors

April 19, 2020

Verastem Oncology Announces Presentation of Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors at the American Association for Cancer Research 2020 Virtual Annual Meeting I

April 12, 2020

Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results

March 10, 2020

Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs

February 27, 2020

Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors

February 27, 2020

Verastem Oncology Announces Dosing of First Patient in CSPC’s Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma

January 28, 2020

Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766

January 7, 2020

Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

December 6, 2019

Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)

November 24, 2019

Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award

November 12, 2019

Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048

November 11, 2019

Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

November 5, 2019

Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress

October 28, 2019

Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress

October 22, 2019

Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019

October 16, 2019

Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

October 6, 2019

Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma

October 2, 2019

Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies

October 2, 2019

Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference

September 25, 2019

← Newer news releases

Calls

Decks

The 5 newest of 55 decks. Every deck is listed under its year.